Aravive, Inc. (ARAV) SEC Filing 8-K Material Event for the period ending Friday, April 1, 2022

Aravive, Inc.

CIK: 1513818 Ticker: ARAV

View differences made from one to another to evaluate Aravive, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aravive, Inc..


Assess how Aravive, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aravive, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Ticker: ARAV
CIK: 1513818
Form Type: 8-K Corporate News
Accession Number: 0001437749-22-008177
Submitted to the SEC: Mon Apr 04 2022 4:16:31 PM EST
Accepted by the SEC: Mon Apr 04 2022
Period: Friday, April 1, 2022
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Other Events
  3. Vote of Security Holders

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: